Posted On: 07/22/2014 7:02:47 AM
Post# of 30067
GC stated revenue guidance would be provided after LymPro's specificity and sensitivity test results are released - assuming that to be at the UN Summit on 7/31.
If LymPro's JV Partner hs not been informed of these same test results, how can AMBS and the JV Partner issues revenue guidance?
This information is critical in being able to conduct feasibility studies, market analysis and marketing guidance, for both the US and oversea's distribution efforts.
Risk may have more to comment on this topic, as we've been conversing on this same issue for the past few weeks.
All said, I'm not indicating that this is a bad - but rather curious to know more specifics as to how a diagnostic makes it way from pre-test result announcement to final revenue guidance projections....
If LymPro's JV Partner hs not been informed of these same test results, how can AMBS and the JV Partner issues revenue guidance?
This information is critical in being able to conduct feasibility studies, market analysis and marketing guidance, for both the US and oversea's distribution efforts.
Risk may have more to comment on this topic, as we've been conversing on this same issue for the past few weeks.
All said, I'm not indicating that this is a bad - but rather curious to know more specifics as to how a diagnostic makes it way from pre-test result announcement to final revenue guidance projections....
(0)
(0)
